StemCell Therapy

KEY POINTS

The human race has always been on the lookout for better ways to improve health and longevity. While it is an undeniable fact that no one is going to live forever, there is always that desire to add just a little bit more years to their lives.

In fact, many people want to enjoy their retirement and watch their grandchildren grow without having to worry about acquiring serious health ailments or diseases. The good news is that this is possible with the help of carefully chosen foods and diet.

A new study has shown that particular food groups could help you live longer. Two of these food groups even came as a surprise to researchers. food groups for increase of life expectancy Photo: ExplorerBob - Pixabay

A New Study

Fresh evidence has been offered by a recent study conducted by US researchers. Involving over 37,200 adults, the new study provides strong evidence that both low-fat and low-carb diets aid in improving longevity. Their findings may put to rest the never-ending low-fat versus low-carb diet when it comes to eating healthy.

According to the new study, diets that contain lots of processed meats and refined carbs may shorten your lifespan. At the same time, researchers say that whole grains, healthy fats, vegetables, and nuts are among the best foods to consume to enjoy a longer and healthier life.

Evidence from the study strengthens the findings of earlier studies proving that diets rich in both healthy carbs and healthy fats could help you live life past 100.The study also took note of the fact that mortality may strongly depend on the quality, as well as food sources, of macronutrients. Life longevity with these types of foods is hugely determined on whether they are loaded with low-quality carbs and processed fats. Many are aware these low-quality carbs and processed fats are bad for the health. These include red meat, white bread, and sugar.

Zhilei Shan, the author of the study and a Harvard University research scientist, said that it does not matter whether people opt for low-fat or low-carb diets. What matters most is the quality of the macronutrients they receive.

Another food expert, Dane Buettner, agreed and also said that every longevity diet in the world has four pillars, namely, greens, beans, whole grains, and nuts. Buettner has examined the diets of people living in the Blue Zones all over the world, which saw people living over 100 with regularity.

Foods to Be Consumed

The studys findings solidified past researches and studies pointing to plant-based diets. This diet contains lots of nutritious phytochemicals, vitamins, fiber, and minerals. In short, consume only foods that come straight from the earth and not out of some machine sitting in a factory.

Original post:
Improve Your Life Expectancy By Including These 2 Surprising Food Groups - International Business Times

Later this evening, the latest inductees to the Baseball of the Fame will be announced, with one or perhaps two voted in by the BBWAA. The only question with Derek Jeter is whether hell be a second unanimous inductee, and Larry Walker likely to end up right on the knifes edge in his last year of eligibility (my gut is hell fall short despite sitting at over 83% of the 211 known ballots at the time this was published).

Its particularly interesting that these two could make up the 2020 class. At a high level, they had a very similar level of on-field value, with Walker actually edging out Jeter by bWAR 72.7 to 72.4 (Jeter has a more significant edge in fWAR, 73 to 68.7). They even rate similarly by Jay Jaffes JAWS system, with Walker coming in at 58.7 to Jeters 57.4. Of course, off-field factors all the dominant reason to explain the discrepancy in support: Jeter being a career Yankees (Re2pect and all that jazz); Walkers numbers discounted for a significant amount of his career coming in Coors.

In a broader sense however, the way that similar level of on-field production was achieved couldnt have been more different. Jeter played a 20 year career, in which he came to the plate 700 or more times in 10 of them and at least 600 in 17 of them. His 12,602 plate appearances rank 10th all-time as a result of that combination of durability and longevity.

To some extent then Jeter was a compiler: he amassed big counting totals not because of an elite level of productivity, but by being on the field. Its not an entirely fair label since he was objectively very good in terms of productivity, but it shows up in his lack of black ink looking at his player page. Twice he led the league (and in fact MLB) in hits, another time in runs (which isnt even totally a reflection of him), and then the other five are for PA. Never did he lead the league in a rate statistic.

By contrast, Walker was not blessed with such durability, routinely missing time with injuries. While his 17 seasons is not that far behind Jeter, only once did he come to the plate more than 601 times. Thus he only came to the plate 8,030 times, ranking 277th all-time. Thats still a pretty prolific total, speaking to how good he was and hence the quotation marks, but its a low total by Hall of Fame standards. For players active after World War II, theres only 11 inductees with less than 8,000 PA, and most of those involve contextual factors (military service, catchers, colour barrier).

But when he was on the field, he was really good. Even adjusting for Coors Field, he was roughly 40% more productive than the average player per PA (including defensive value). I dont think theres a term for the opposite of a compiler, but Im inclined towards the metaphor of a shooting star: a dazzling bright light arcing across the sky, but that doesnt last long.

Should one prefer a Walker to a Jeter or vice versa? Fundamentally, this is a normative question about what the Hall of Fame should be; everyones mileage will vary especially when it comes to the margin. Descriptively however, its clear that compilers prevail. With Harold Baines inducted last year, Rusty Staub is the only non-active/non-ballot player with at least 10,800 PA not in the Hall of Fame (other than Rafael Palmeiro for PED reasons).

To some extent this is logical theres a very high minimum baseline required to just be able to accrue 10,000 plate appearances. By contrast, absent a contextual factor like those described above, a player under 9,000 career PA making the Hall of Fame is very much an exception regardless of how high the level of productivity (Bobby Grich, Dick Allen, Reggie Smith, etc).

The epitome of this dynamic is actually playing out with two players on the ballot for the third time. Omar Vizquel played 24 big league seasons thanks to his defensive wizardry, his 12,013 PA slotting in 21st all-time. As a result, despite being almost 250 runs below average as a hitter, he ended up just shy of the mythical 3,000 hits (2,877) that represents automatic enshrinement which is supporters point to.

Lets be clear, he had a wonderful career, and hes easily in the top 5% of baseball players historically. This isnt to run him down. But with 45 WAR, hes well shy of Cooperstown standard. Equally, it is almost certain he will one day be inducted. Hes currently sitting at just about 50% support, which actually tends to be increase when non-public votes are tallied. He might not build to the 75% needed, but hell build from this point and only one player ever to get 50% on a writers ballot hasnt been subsequently inducted.

On the flip side is Andruw Jones, who played 17 seasons with just 8,663 PA, but nonetheless put up around 65 WAR (63 bWAR, 67 fWAR). Thats already on the short end by Hall of Fame standards, but its compounded by six of those were partial seasons mostly at the end of his career as a complementary player. Almost all of his value came from his 1997-2007 peak. Not only was he at least Vizquels defensive equal in centre, but he was an impact middle of the order hitter.

Yet even with some big gains this year, hes only at about 25% support (and probably closer to 20% in the end). Its not impossible, but its hard to see him gaining enough support to make it in. Perhaps in the end the productive part of his career was just too short longevity certainly counts. But it speaks volumes I think that if you add the two careers together, you get 41 seasons of which Vizquel contributes 60%. But if you make a list of the top 10 single seasons, perhaps two of them belong to Vizquel (1999 for sure)?

When it comes to balancing peak and longevity, Im definitely in the camp of the former. Give me Jones over Vizquel. Give me Grich over Luis Aparicio. Give me Johan Santana over Jack Morris (or better yet, Dave Steib over Morris). We havent even got to pitchers.

While historically a lot of this was based on achieving counting milestones that required longevity, more recently I think part of the problem is the prevalence of WAR. Dont get me wrong, its a very useful construct. But its an artificial one all the components are measured relative to average, and then at the end theres a translation to make zero replacement level, roughly the level where talent is readily available.

This is very useful most analysis, but it doesnt really apply at the Hall of Fame level though. Routinely, players who were solid everyday regulars (or better) dont get any support or are even left off the ballot. That is to say, for purposes of the Hall of Fame, average is replacement level. And maybe even well higher than that (Rafael Furcal and Eric Chavez were both almost 40 WAR and 10+ WAA, and have a combined one vote on a ballot that isnt crazy crowded).

So in my view, a much better standard for the Hall of Fame is Wins Above Average (WAA). By this measure, Jones (36 WAA) far outclasses Vizquel (5 WAA). Walkers 48 WAA is far ahead of Jeters 31. Using WAA sharpens the contrast longevity and star level productivity.

To finish up and perhaps further elicudate the contrast, I made two starting lineups. The first is compilers who are in the Hall of Fame (not all dont belong objectively, theyre just on the compiling end of the spectrum). The second is shooting stars who have been passed over for Cooperstown.

Overall, shorter career players actually end up a slightly higher WAR total even in a much smaller amount of playing time. Even if all the missing playing time had to be backfilled with ordinary players rather than all-time greats, I think they come out ahead.

See the original post here:
The Baseball Hall of Fame, and longevity versus peak - Bluebird Banter

Turns out you can start fighting the biological agents of aging with your morning cup of coffee. According to new research published in the journal ofOxidative Medicine and Cellular Longevity,the simple decision to opt for skim or 1% milk as opposed to whole milk can add years to your life.

The new pioneering study conducted at Brigham Young University effectively knee-caps recent reports challenging dairys contribution to optimal health.

The authors write in the reports abstract:Investigations evaluating the effect of adult milk consumption on health and disease have produced inconsistent findings. Some studies indicate that the consumption of cows milk promotes health, while others show that it increases risk of disease and mortality. Numerous investigations highlight the mixed results. Overall, the findings highlight an association of increased biological aging in U.S. adults who consumed high-fat milk. The results support the latest Dietary Guidelines for Americans (20152020), which recommend consumption of low-fat milk, but not high-fat milk, as part of a healthy diet.

A lengthy analysis of the beverage habits of 5,834 Americans not only motioned low-fat milks impact on longevity, but it also uncovered a slew of other benefits.

Nearly 50% of the entire study pool drank some form of milk every single day and a quarter consumed dairy on a weekly basis. Of these, a little more than 30% drank whole milk, exactly 30% drank 2%, 17% drank skim, 13% preferred non-dairy alternatives like soy or almond and a modest 10% regularly drank 1% milk.

Participants who routinely drank either skim or 1% milk aged around four and half years slower than their 2% milk-loving counterparts.

The low-fat milk drinkers even demonstrated slower genetic aging markers than the individuals that privileged nondairy milk. Of course, this adverse correlation was the most pronounced among habitual whole milk drinkers.

You might recall Ladders recent mediation on the physiological hallmarks of aging. It was an in-depth look at the function of telomerestheends of chromosomes that gradually shrink as a result of repeat cell replication. In other words, the older we get, the shorter they get.

This process was thought to be an unalterable one butin the last few decades,experts have motioned several different ways we can protect these chrome-caps and fend off aging.

The researchers behind this new report, for instance, concluded that every 1% increase in milk fat imbibed was associated with a 69 base pair telomere length-decrease. This is the equivalent offour and a half years of increased aging.

Participants who drank whole milk considerably more often than they drank skim or 1% milk expressed a 145 base pair telomere length decrease. Even with these insightful citations in the chamber, the studys lead author, professor Larry A. Tucker,has no doubt that the scholarly wrangle surrounding the health merits of long-time dairy consumption will survive. And rightly so. On the key question, theres still a fair share of unknown left to discover.

Milk is probably the most controversial food in our country, Tucker said in a press release . If someone asked me to put together a presentation on the value of drinking milk, I could put together a one-hour presentation that would knock your socks off. Youd think, Whoa, everybody should be drinking more milk. If someone said do the opposite, I could also do that. At the very least, the findings of this study are definitely worth pondering. Maybe theres something here that requires a little more attention.

See original here:
Drinking this every day can reverse the effects of aging - Ladders

Modern diet science is much more charitable towards carbs than fads of old. New data assures us thatcarbohydrates areessential to a balanced dieteven when weight loss is an immediate objective.

But a new study published by Harvard researchers in the JAMA Internal Medicine Journal found that not all carbs are equal.

The study, which featured more than 35,000 Ameican adults aged 20 and older, found that the quality of a food group impacted longevity significantly more than the presence of a food group in a given regimen. Despite past studies, a low-fat diet isnt indicative of an effect, sustainable diet.

In this study, overall low-carbohydrate-diet and low-fat-diet scores were not associated with total mortality, researchers said. Unhealthy low-carbohydrate-diet and low-fat-diet scores were associated with higher total mortality, whereas healthy low-carbohydrate-diet and low-fat-diet scores were associated with lower total mortality.

These findings suggest that the associations of low-carbohydrate and low-fat diets with mortality may depend on the quality and food sources of macronutrients.

Since the weight loss market is such a lucrative industry and the medias obsession with diets, it has been argued by some that the market makes a point to blur the line between personal objectives and dietary guidelines. If someone needs to lose weight for health reasons or even for cosmetic purposes, there are healthyand expedient ways to do so.

While carbohydrates give us energy, if the energy isnt used after consumption then theyre stored in our muscles and liver for later. Eventually, if unused, the carbohydrates will turn into fat. Low-carb diets, if adhered to correctly, promote weight loss by limiting the number of carbs we need to use before they become stored as fat. This method works for about six months but fails to be a sustainable system in the long term.

Relying on meats for energy at the expense of carbs is linked toa higher risk for cancer and early death.Restricting carbohydrates is the quickest way to drop weight as long as you apply this restriction to a considered timeline.The Dietary Guidelines for Americas recommend that carbohydrates make up between 45% to 65% of your daily calories. Thats about225 grams for women and to 325 grams for men.

Unlike previous studies, the researchers not only took the number of carbs into account but also the source of carbs consumed. This prerequisite provided an important insight into the role balance plays into longevity and dietary guidelines. When accounting for the total number of person-years (297,768), 4,866 total deaths occurred. Researchers said low-carbohydrate-diet and low-fat-diet scores were not associated with total mortality, but a healthy low-carbohydrate diet and a healthy low-fat diet were associated with lower total mortality.

Our findings show clearly that the quality rather than the quantity of macronutrients in our diet has an important impact on our health, said Zhilei Shan, a postdoctoral researcher at Harvards Department of Nutrition, in a press release. The debate on the health consequences of low-fat or low-carbohydrate diets is largely moot unless the food sources of fats or carbohydrates are clearly defined.

The recommended carb intake can be obtained in three different ways: sugars, starches, and fibers. Each has its own set of health benefits. In addition, fruits, vegetables, milk, grains, seeds, and nuts are a good varied placed as well. When it comes to addressing mortality statistics, there are confounding factors to consider. Carbs, for instance, primarily provide our bodies with energy. If fibers are consumed in your daily carb intake, you lower your risk for cardiovascular disease and type-2 diabetes.

One recent study found that people who ate at least five fruits a day lived roughly three-years longer than those who didnt. Earlier this week, a new report about habitually consuming skim milk reversed the aging process by an average of four-and-a-half-years.

Read the rest here:
This Harvard study might put the end to the carbohydrates war - Ladders

Image Credit: SeventyFour/Shutterstock.com

Tribology refers to the science of how surfaces in natural and artificial systems interact in relative motion. The principles of lubrication, friction, and wear are key to the discipline. As it is a highly interdisciplinary field, scientists from different areas of the scientific community are often drawn together to help solve problems in tribology.

To advance knowledge of tribology and to make innovations in this area, collaborative efforts from experts in biomedical science, chemistry, chemical engineering, computer science, mechanics, engineering, manufacturing, mathematics, physics, and more are needed.

While the science of tribology influences numerous industries, the automotive and medical sectors are those that particularly rely on its knowledge and innovations to improve its products and raise its level of quality.

Problems presented by the automotive industry are mostly fueled by the growing demand to produce components that have lifetime guarantees. The products need to be created with higher levels of quality, as consumers require parts with longevity, not only in terms of how long it will last without breaking but also in terms of how the components function over their lifetime.

The demands of the medical industry are similar. There is a growing demand for medical prosthetics, for example, that are easy to install and last a lifetime. Both industries are facing challenges in tribology; they need to develop components with surfaces that do not cause wear as they interact with each other over extended periods. Components also need to be developed in a way that prevents a change in how they behave as they continue to be in constant contact with their surroundings, offering the ability to do the same job repeatedly and to the same level of quality.

The solution relies heavily on understanding how two surfaces interact with each other. Recent advances in tribology have seen the increase in the development of surface texture of coatings to offer friction-free use.

The monitoring of these coatings is essential to understanding how effective they are, and how this may influence the longevity of a component. The task of monitoring can be difficult, but recently, sensors have been employed to conduct this task efficiently and accurately.

The past decade or so has seen the advent of the use of sensors to help solve tribology problems. The coatings that are being tested for use in numerous applications have benefited from the addition of embedded sensor layers within the coating.

These sensor layers have been designed to produce distinctive luminescence spectra in response to laser illumination, which makes it possible to measure the wearing of the coating by measuring changes in the amount of light transmitted back. This offers information on the changing thickness of the coating.

Coatings are designed to ideally last a lifetime, protecting the component from wear and extending the longevity of the product. Using embedded sensors to measure wear methodologically allows scientists to make accurate calculations about how coatings will influence the products that they are intended for. It also helps scientists to innovate new and better coatings by allowing them to see how different coating compositions function. It also enables them to make these innovations faster because they have a direct and accurate way of measuring the coatings effectiveness.

Tribology will likely be positively impacted by the use of sensors to help develop more effective coatings. This may lead to the development of more superior products in the automotive and medical industry, as well as others. Sensors will likely play a role in the continuing improvement of quality and longevity of a wide range of components and products.

https://www.sciencedirect.com/science/article/abs/pii/S0167892208700300

https://www.sciencedirect.com/science/article/abs/pii/S0043164808000471#!

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

See more here:
Solving Problems in Tribology with Sensors - AZoSensors

David Hogness

courtesy stanford medicine

David Hogness, a biochemist, geneticist, and developmental biologist at Stanford University, died at his home on December 24. He was 94 years old.

Hogness is well known for a series of experiments during the 1970s and 1980s that were instrumental in launching both molecular genetics and genomics, according to a university statement.

His lab brought molecular biology to Drosophila, discovered the first core promotor element in eukaryotes, cloned the Hox genes, studied the basis of steroid hormone signaling, the list goes on and on. He was a giant, says biologist Mark Peifer of the University of North Carolina in a tweet.

Hogness was born in Oakland, California, on November 17, 1925, and grew up in Chicago. In 1949, he received his bachelors degree in chemistry from Caltech, where he also earned his PhD in biology and chemistry in 1952.

While a faculty member at Washington University in St. Louis, Hogness studied bacteriophage lambda and created the first physical maps of genes along DNA, according to the statement. He joined Stanfords newly formed biochemistry department in 1959, and during a sabbatical in 1968, shifted his focus to Drosophila.

In a 1972 grant proposal, Hogness described the concept of chromosomal walkingnow known as positional cloninga technological breakthrough that many consider to be the founding of genomics, according to Stanfords statement.Hognesss 1975 paper published in PNAS detailed colony hybridization, a novel method of isolating cloned DNA. Three years later, Hogness discovered the Goldberg-Hogness box, now called the TATA box, a non-coding promoter sequence where transcription is initiated in archaea and eukaryotes (prokaryotes have a homolog called the Pribnow box). Another landmark study published in the early 1980s demonstrated the ability to clone the gene underlying any genetic trait, and simultaneously proved there were genes specifically devoted to regulating normal development, says Richard Lifton, the president of Rockefeller University and a former student of Hogness, in the press release. Its one of the great papers in the history of biology.

Daves genius was to realize that the recombinant DNA technologies newly developed at Stanford, which allowed researchers to isolate and replicate to very high copy numbers distinct segments of DNA, could be used to map the locations of the DNA segments to specific bands on the polytene chromosomes, developmental biologist Philip Beachy says in the statement.

Hognesss awards include the March of Dimes Prize in Developmental Biology in 1997, the Lifetime Achievement Award of the Society for Developmental Biology in 2002, the Thomas Hunt Morgan Medal in 2003, and the Warren Alpert Foundation Prize in 2013.

Hogness is survived by his sons.

Amy Schleunes is an intern atThe Scientist. Email her ataschleunes@the-scientist.com.

Read more:
David Hogness, Revolutionary of 20th Century Genetics, Dies - The Scientist

Over the years, the Simons Foundation Autism Research Initiative (SFARI) has made contributions to selected Gordon Research Conferences (GRCs) with the aim of helping to defray the travel and/or conference costs for graduate students, postdoctoral fellows, trainees and other scientists attending these conferences.

As part of SFARIs efforts to encourage diversity and inclusion at scientific meetings and in autism research, SFARI will now require that GRCs organizers allocate all SFARI-donated funds to support attendance specifically of early career (pre-tenure) women, early career trainees from historically underrepresented groups, and scientists from the following ethnic and racial groups: Hispanic or Latino, American Indian or Alaska Native, Black or African American, Native Hawaiian or Other Pacific Islander.

We hope that, by lowering barriers to conferences attendance, SFARI support will promote opportunities for scientific growth and collaborations that can help build a more inclusive research community and advance the field, says SFARI director Louis Reichardt.

SFARI supports GRCs that are focused on topics of relevance to the study of autism spectrum disorder. These may include but are not limited to genetics, molecular mechanisms, brain circuits, systems and behavior, as well as novel technological advances in neuroscience. GRCs may be organized and/or attended by SFARI Investigators and provide unique opportunities to network with leaders in autism research and learn more about the latest findings in the field.

Eligible researchers who are planning to attend SFARI-supported GRCs this year are encouraged to contact the conference chairs to inquire about funding availability.

In 2020, GRCs for which SFARI funds may be available include:

Thalamic circuits for perception, cognition and actionVentura, California, United StatesFebruary 1621, 2020

Functions of the basal ganglia from thought to actionVentura, California, United StatesMarch 813, 2020

Systems neuroscience and genetic approaches to study sleep regulation and functionLucca (Barga), ItalyMarch 813, 2020

Novel technologies to advance discovery of disease mechanisms and therapeutics for fragile X and autismLucca (Barga), ItalyMay 31June 5, 2020

Context-specific synaptic functionLucca (Barga), ItalyJune 2126, 2020

Emerging technologies to study nervous system development, function and neurological diseaseHong Kong, ChinaJuly 510, 2020

Circuits and specializations for behavioral interactions in acoustic communicationNewry, Maine, United StatesJuly 1924, 2020

Linking brain circuits to behavior: Novel methods and biological insights derived from optogenetic approachesNewry, Maine, United StatesJuly 1924, 2020

Neural circuits, dynamics and computations of cognition and behaviorNewry, Maine, United StatesJuly 2631, 2020

Building the nervous system: Insights from development, evolution and diseaseNewport, Rhode Island, United StatesAugust 914, 2020

Molecular and network complexity in the epileptic brainCastelldefels, SpainAugust 1621, 2020

See the article here:
SFARI funds to support diversity at Gordon Research Conferences - SFARI News

Each week, The Dailys Science & Tech section produces a roundup of the most exciting and influential research happening on campus or otherwise related to Stanford. Heres our digest for the week of Jan. 12 Jan. 18.

The Human Screenome Project collects 30 million data points

The Human Screenome Project, a multidimensional map of peoples digital lives, collects data and records which websites users browse online, a Jan. 15 commentary article in Nature reports.

Previous screen studies have relied on people self-reporting their screen time, which can lead to inaccuracies. Although studies have been using software to log total screen time and time between mobile applications, there is no method used to monitor digital interactions of how people use mobile applications.

The Stanford Screenomics Lab currently has 600 participants in the study and over 30 million data points.

No matter what you study, whether its politics, addiction, health, relationships or climate action, if you really want to understand peoples beliefs and behaviors, you really need to look at their screenome, because so much of our lives is now filtered through our digital devices, pediatrics and medicine professor Thomas Robinson told Stanford News.

Many of the things we once did face-to-face are now reflected and recorded on our screens, whether it is banking or deciding what to eat or making friends or playing games or dating or exercising or discussing politics, and so on. Robinson added.

Four aging metabolic pathways identified in humans

To better understand the biological mechanisms behind aging, a Jan. 13 Nature Medicine study defined four ageotypes that indicate how an individuals molecular makeup changes as one ages.

Our study captures a much more comprehensive view of how we age by studying a broad range of molecules and taking multiple samples across years from each participant, genetics professor and chair Michael Snyder told Stanford Medicine News. Were able to see clear patterns of how individuals experience aging on a molecular level, and theres quite a bit of difference.

The researchers used 43 men and women between 34 and 68 years old to identify four ageotypes in which aging biomarkers are commonly observed in metabolic, immune, hepatic and nephrotic pathways. For example, people who are metabolic agers may be at a higher risk for developing diabetes or have elevated blood sugar levels as they become older.

The ageotype is more than a label; it can help individuals zero in on health-risk factors and find the areas in which theyre most likely to encounter problems down the line, Snyder told Stanford Medicine News. Most importantly, our study shows that its possible to change the way you age for the better. Were starting to understand how that happens with behavior, but well need more participants and more measurements over time to fully flesh it out.

Analyzing DNA in soil samples to track animals

Analyzing DNA left behind by animals in soil samples may be more effective in tracking animals than the traditional camera traps currently used, a study published on Jan. 14 in Proceedings of the Royal Society B found.

Led by environmental biology professor Elizabeth Hadly, the team is studying how to better monitor biodiversity, which is crucial to conservation efforts. The researchers studied environmental DNA (eDNA) found in soil samples derived from animal hair, feces, skin and saliva.

The findings suggest that studying eDNA provides certain advantages over the traditional camera traps, hidden recording devices used to track animal activity. eDNA can detect genetic traces of animals that were too small for the camera trap to visually capture an image. Additionally, eDNA is useful in distinguishing similar-looking species compared to using cameras.

Its overall accuracy, combined with decreasing costs of genetic sequencing and new portable sequencers, makes eDNA a likely candidate to become the standard for biodiversity surveys in the next decade, Kevin Leempoel, a postdoctoral research fellow in biology, told Stanford News.

Contact Derek Chen at derekc8 at stanford.edu.

Go here to see the original:
Research Roundup: Human Screenome Project, four pathways in aging and a new DNA-based method to track animals - The Stanford Daily

FRANTZ PNC Bank

AARON NIVERT Howard Gardner AARON NIVERT Howard Gardner AARON NIVERT Howard Gardner

Allied Services Integrated Health System

The health system recently welcomed four new board members.

The health system welcomed two new members to its board of directors. Christina Mueller and Jill Murray, Ph.D., will serve on the Allied Services Foundation board of directors.

Mueller, a native of Clarks Summit, earned her undergraduate degree from St. Marys College in Notre Dame, Indiana. The early years of her career were spent in Chicago, where she earned her Master of Business of Administration at Loyola University. While studying at Loyola, Mueller began her career with McDonalds. After graduating, she returned to Northeast Pennsylvania, where she trained and became a McDonalds operator. Today, she assists her family in operating 16 local McDonalds stores. Mueller is actively involved in supporting the work of the Ronald McDonald House of Scranton and in supporting local schools through the McTeacher nights at local McDonalds restaurants.

Murray is incoming president of Lackawanna College. Before accepting this position, Murray served as executive vice president and chief innovation officer for Lackawanna College. Murray earned her Ph.D. in human development from Marywood University and has held teaching positions at Walden University, Kaplan University, Marywood University and the University of Phoenix. She is currently on the board of Maternal and Family Health Services and received the 2018 Non-Profit Board Member of the Year award from the Wilkes-Barre Chamber of Commerce.

The health system welcomed two new members to its board of directors. Jay Brislin, MSPT, and Dr. Sandra Krokos-Kislan will serve on the hospital board of directors responsible for oversight of Allied Services Scranton Rehab Hospital and Heinz Rehab Hospital.

Brislin, vice president of Quantum Rehab, a division of Pride Mobility Products, brings an unrivaled depth of knowledge of complex rehab needs to his role on the rehabilitation hospital boards. Brislin began with Quantum Rehab in 2000 as a rehab specialist, quickly becoming a leader and educator in the arena of complex rehab needs. Brislin was part of the team instrumental in launching some of Quantum Rehabs most innovative products. Today, he oversees a clinically based team dedicated to the most innovative products and inspiring client outcomes. As an industry leader, Brislin is a RESNA member, Friend of NRRTS and NCART participant.

Krokos-Kislan, of Hazleton, is a graduate of Coughlin High School. She received her Bachelor of Science from Wilkes College before earning her Doctor of Optometry degree from the Pennsylvania College of Optometry. Sandra and her husband, Dr. Thomas Kislan, own and manage Stroudsburg Eye Specialists and Hazleton Eye Specialists. Kroskos-Kislan is a member of the board of directors of Burnley Employment and Rehab Services, a division of Allied Services providing employment services for individuals with disabilities in the Poconos.

American Society of Public

Administration

David Allen Hines was recently reelected to the board of directors for the Keystone State (Pennsylvania state) chapter. Hines holds a Master of Public Administration degree from Marywood University in Scranton, and for many years was the deputy director for budget administration for the government of the District of Columbia in Washington, D.C. After returning to the area, for the past several years he has been director of operations for the city of Pittston. A 40-year resident of Kingston, Hines also serves on the national budget and financial policy committee for the Government Finance Officers Association and the board of directors for the Greater Pittston Historical Society.

Healthy Steps Podiatry Center

Dr. Diane Stchur Bray has recently opened the center on Chocolate Avenue in Hershey. Bray, a graduate of Hanover Area High School, received her Bachelor of Science degree in biology and molecular genetics from Kings College, and her doctorate in podiatric medicine from Temple University.

After doing a three-year intensive surgical residency at Our Lady of Lourdes Hospital in Binghamton, New York, Bray then joined a group practice where she provided podiatric care and served as a wound care specialist for the patients of upstate New York for 16 years.

Howard Gardner Multiple

Intelligence

Charter School

The school welcomed four new trustees to its board. New trustees are Laurie Cadden, owner, Laurie Cadden LLC; Sam Ceccacci, former executive director, Scranton-Lackawanna Human Development Agency; Susan Hennemuth, development director, Childrens Service Center; and Aaron Nivert, executive vice president, Nivert Metal Supply.

PNC Bank

The bank recently announced that Judith Frantz, branch manager, has been promoted to vice president.

Frantz is a graduate of Misericordia University with a bachelors degree in business administration. She is also a graduate of Wilkes University, where she went to earn her MBA. She resides in Luzerne.

Carly Caroselli has joined PNC Wealth Management as a vice president and investment adviser.

Caroselli is a graduate of Drexel University with a Bachelor of Science degree in behavioral health. She resides in Scranton.

University

of Scranton

The university has named Julie Schumacher Cohen assistant vice president for community engagement and government affairs. In this position, she will report to the vice president for enrollment management and external affairs and will also work closely with the provost and senior vice president for academic affairs.

In her new role, Schumacher Cohen will work to deepen the universitys community engagement efforts and government affairs activities and strengthen the mission of the university as an anchor institution in our city and region.

Since 2010, she has served as the universitys director of community and government relations.

SUBMIT PEOPLE ON THE MOVE items to business@timesshamrock.com or The Times-Tribune, 149 Penn Ave., Scranton, PA 18503.

Link:
People on the Move - News - Wilkes-Barre Citizens Voice

LabXchange by Amgen Foundation and Harvard's Faculty of Arts and Sciences Reimagines the Science Experience for Students around the Globe

Purpose-Built to Address Educational Barriers With Personalized Instruction

Virtual Lab Simulations Help Students Develop the Science Skills Needed to Solve Tomorrow's Challenges

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Jan. 22, 2020 /PRNewswire/ --The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS)today announced the global launch of LabXchange, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. LabXchange is purpose-built to drive more inclusion in the scientific process and spark collaboration to build creative, team-based approaches to real-world problems.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8490258-amgen-foundation-harvard-labxchange/

"Too many high school and college students lack the opportunity to directly explore the scientific process where you build a hypothesis, understand a method, and determine how to apply it to an appropriate experimental problem," said Robert Lue, Ph.D., principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard. "For many students, science can feel like a collection of facts to memorize which is contrary to what the scientific process is it's a journey that requires bold thinking and deep imagination. With LabXchange, more students can come together and experience the joy of discovery."

Featuring virtual lab experiments developed at LabXchange along with other world-class assets created by validated partners, LabXchange brings the scientific process to life. By simulating key techniques in molecular and cellular biology, like using CRISPR to correct genetic defects, students can explore a wide range of scientific methods and build their acumen in harnessing science to solve real-life problems.

"Everyone needs science, and science needs everyone," said Robert A. Bradway, chairman and chief executive officer at Amgen. "At a time of remarkable scientific progress, we're excited by the potential of LabXchange to educate and inspire both students and lifelong learners of all ages."

LabXchange is designed to level the playing field for students and to promote science literacy for all. Key features of LabXchange include:

LabXchange builds upon other Amgen Foundation programs that support science education, such as the Amgen Biotech Experience and Amgen Scholars that are also at Harvard FAS and institutions around the world. To date, the Foundation has contributed more than $150 million to advancing science education programming globally as part of its mission to facilitate global collaboration on the United Nations Sustainable Development Goals (SDGs), notably SDG #4 on Quality Education, but also SDG #3 on Good Health and Well-Being.

For more information, please visit http://www.LabXchange.org, and engage with us via @LabXchange on Twitter using #ScienceMadePossible.

About the Amgen Foundation The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated over $300 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars and the Amgen Biotech Experience. For more information, visit AmgenInspires.com and follow us on Twitter @AmgenFoundation.

About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980,Amgenhas grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Story continues

For more information, visitwww.amgen.comand follow us onTwitter @Amgen.

About the Faculty of Arts and Sciences at Harvard University The Faculty of Arts and Sciences is the largest of the seven faculties that constitute Harvard University and is the only division of the university responsible for both undergraduate and graduate education. FAS advances knowledge, improves learning, and shapes leaders.

For more information, visit http://www.fas.harvard.edu/

CONTACT: Amgen, Thousand OaksJessica Akopyan, 805-447-0974(Media) TrishHawkins, 805-447-5631 (Media)

Harvard Faculty of Arts and Sciences, CambridgeRachael Dane, 617-456-0106 (Media)

With LabXchange's interactive lab experiments, students have access to one of the most central aspects of being a scientist: working in a laboratory.

LabXchange gives students access to a library of world-class educational videos, interactive simulations and personalized instruction to aid them in their scientific discovery.

Every student deserves an equal opportunity to prepare for and be successful in science, regardless of income, race gender or geography. LabXchange ensures this opportunity by providing students access to free online science education and inspiring lifelong learning.

LabXchange brings the experience of working and learning science in a lab straight to students. Through virtual lab experiments, high-quality videos and online collaboration with others in the global science community, students can experience the scientific process for themselves.

View original content:http://www.prnewswire.com/news-releases/free-labxchange-science-education-accelerator-launched-by-amgen-foundation-and-harvards-faculty-of-arts-and-sciences-300990930.html

SOURCE Amgen

See more here:
Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences - Yahoo Finance

This unique report provides UK sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in RandD, collaborative arrangements, and business strategies.

New York, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "2020 U.K. Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies" - https://www.reportlinker.com/p05838907/?utm_source=GNW

Competitive Assessments

- Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - Decode Genetics - Diadexus - Eiken Chemical - Elitech Group - Enzo Biochem - Exact Sciences - Fujirebio - Grifols - Hologic - Illumina - LabCorp - Leica Biosystems - Li-Cor Biosciences - Myriad Genetics - Ortho-Clinical Diagnostics - PerkinElmer - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens Healthineers - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher

List of Tables

UK Molecular Diagnostics Market by Major Supplier UK HIV/Hepatitis NAT Market Reagent Sales by Major Supplier

Contains 121 pages and 2 tables

Read the full report: https://www.reportlinker.com/p05838907/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

More:
2020 U.K. Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies - Yahoo Finance

There is an entire cinematic subculture devoted to sharks that find ingenious ways to travel on land, be it via sharknado, genetic hybridization, or occult forces. Meanwhile, in the real world, there actually is a family of sharks that have evolved to walk on land, though they are much smaller, cuter, and less ravenous for human flesh than their counterparts on film.

These walking sharks belong to the Hemiscyllium family, which is the newest lineage of sharks on Earth, according to a study published on Monday in the journal Marine and Freshwater Research. Using specially adapted fins, the sharks are able to pull themselves across reefs in their tropical Indo-Australian habitat, even when they are not submerged by water.

Theyre incredibly cute little animals and are really more like a gecko walking around than a shark, said co-author Mark Erdmann, a coral reef ecologist at the California Academy of Sciences, in a call.

They are not big swimmers, added Erdmann, who also serves as vice president of the Asia-Pacific Field Division of Conservation International, an American nonprofit environmental organization. They stay on the same reef where they are born. They are very much homebodies.

While these ambulatory skills have been documented in previous studies, Erdmann and his colleagues shed new light on the familys evolutionary origins by analyzing DNA from the nine currently recognized species of Hemiscyllium. The team conducted a molecular phylogenetic analysis of the sharks, which means they used DNA sequencing to figure out the sharks genetic relationships to each other, and the wider shark lineage.

The results revealed that walking sharks are the youngest branch of the shark family tree, which dates back about 450 million years.

With our molecular clock, weve been able to show that this group really only branched off from their nearest ancestor about nine million years ago and theyve been actively radiating ever since, Erdmann said. Obviously in human terms, that still seems like a long time ago, but for sharks, and for speciation in general, thats actually very recent.

This timeline of speciation coincides with major geological changes that were occurring as the Australian continental plate slammed into landforms north of it. These tectonic processes, accompanied by volcanic eruptions, have repeatedly scrambled the region over millions of years like a giant island disco, as Erdmann described it.

Walking sharks weathered these geological storms by flourishing in newly created shallow reefs, where they gained the ability to wriggle overland to remote tidal pools. The sharks, which typically measure a foot or two in length, have also adapted to endure the oxygen depletion that occurs in these isolated pools at low tide.

But despite these amazing adaptations, walking sharks are vulnerable to natural disasters, such as tsunamis and volcanic eruptions. The fact that they have such tiny little distributionseach one has a small pocket like a bay or an archipelagomakes them just intrinsically susceptible to large perturbations and extinction events, Erdmann said.

The sharks are also increasingly facing anthropogenic pressures, including rising popularity as an aquarium attraction and potential habitat loss due to coastal development. For that reason, conservationists have been working to secure more protections for walking sharks, and have succeeded in adding three of the nine species to the International Union for Conservation of Nature Red List.

Erdmann and his colleagues plan to conduct many more expeditions to the Indo-Pacific reefs where these animals thrive, in order to learn more about their conservation requirements and the extent of their range and varieties.

The genetics very much confirm that these are a very young radiation and they seem to still be actively speciating, so we reckon that theres probably a good chance of a few more species of walking shark out there, he said. This shows to us that they very much are still an active part of our evolving planet, and thats really good news.

Read the original:
Walking Sharks Are the Newest Branch of the Shark Family Tree - VICE

CHICAGO, Jan. 20, 2020 /PRNewswire/ -- According to the new market research report "Gene Therapy Marketby Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024", published by MarketsandMarkets, is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% from 2019 to 2024.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of the market.

The non-viral vectors segment accounted for the largest share of the market, by vector, in 2018

The Gene Therapy Market, by vector, has been segmented into viral and non-viral vectors. Non-viral vectors accounted for the largest share of the market in 2018. This is mainly attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

Browsein-depth TOC on "Gene Therapy Market" 127 - Tables25 - Figures 129 - Pages

The demand for gene therapies for the treatment of cancer is expected to grow at a high rate

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. However, the cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the increasing incidence of cancer and the rising demand for CAR T-cell therapies.

Get 10% Customization Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857962

North America is the largest regional market for gene therapy products

The global Gene Therapy Market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. Moreover, the North American market is estimated to register the highest growth rate during the forecast period. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

The prominent players operating in the Gene Therapy Market include Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Itlay), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US).

Browse Adjacent Markets @Biotechnology MarketResearch Reports & Consulting

Get Special Pricing on Bundle Reports:https://www.marketsandmarkets.com/RequestBundleReport.asp?id=122857962

Browse Related Reports:

Regenerative Medicine Marketby Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

Viral Vector Manufacturing Marketby Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023

About MarketsandMarkets:

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : +1-888-600-6441Email: sales@marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp Research Insight:https://www.marketsandmarkets.com/ResearchInsight/gene-therapy-market.asp Visit Our Website:https://www.marketsandmarkets.com

Logo:https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

Read more:
Gene Therapy Market Worth $13.0 Billion by 2024 - Exclusive Report by MarketsandMarkets - PR Newswire UK

We, Global Marketers.biz, after comprehensive analysis, have introduced a new research study on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market. The report provides a unique competitive analysis of the size, segmentation, competition, trends, and outlook in the manufacturers operating in the industry. It covers the key manufacturers profiles in detail along with market entry strategies, production analysis, market share, revenue forecast and regional analysis of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry. It particularly delivers wide-ranging analytical information on regional segmentation.

Download Free Sample PDF Report Inquire Before Buying

The researchers team presents the analytical data and figures in the report in an effectual way with the help of graphs, diagrams, pie charts, and other pictorial illustrations. The report focuses on providing the clients and other readers with all the necessary information regarding Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market share, new product launch, applications, provinces, businesses, economic growth, and supply and demand rate. It examines the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry potentials for each geographical region with respect to the client purchasing patterns, macroeconomic parameters, market demand and supply states, and evolution rate.

This study considers the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market value and volume generated from the sales of the following segments:

Growth Drivers and Industry Trends:

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market is divided into different segments with reference to the geographic, types, applications, and manufacturers. Our team of scholars has followed a focused and realistic research outline in order to inspect the vital market dynamics like drivers, restraints, and opportunities in many areas across the world.

Regional Analysis:

The report covers a forecast and an exploration of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market on a global and regional level. The historical data is given from 2015-2020 and the forecast period is from 2020-2026 based on revenue (USD Billion). The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry was estimated at XX Million US$ in 2020 and is probable to grasp XX Million US$ by 2026, at a CAGR of XX% throughout 2020-2026.

Key Focused Regions in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market:

Table of Content

1 Global Market Overview

1.1 Scope of Data

1.1.1 Scope of Yields

1.1.2 Scope of Companies

1.1.3 Scope of End-Use

1.1.4 Scope of Product Type

1.1.5 Scope of Geographies

1.2 Global Market Size

2 Regional Market

2.1 Regional Sales

2.2 Regional Demand

2.3 Regional Trade

3 Key Manufacturers

3.1 Company A

3.1.1 Company Info

3.1.2 Product & Services,

3.1.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.1.4 Recent Expansion

3.2 Company B

3.2.1 Company Info

3.2.2 Product & Services

3.2.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.2.4 Recent Expansion

3.3 Company C

3.3.1 Company Info

3.3.2 Product & Services

3.3.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.3.4 Recent Expansion

3.4 Company D

3.4.1 Company Info

3.4.2 Product & Services

3.4.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.4.4 Recent Expansion

3.5 Company E

3.5.1 Company Info

3.5.2 Product & Services

3.5.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.5.4 Recent Expansion

3.6 Company F

3.6.1 Company Info

3.6.2 Product & Services

3.6.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.6.4 Recent Expansion

3.7 Company G

3.7.1 Company Info

3.7.2 Product & Services

3.7.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.7.4 Recent Expansion

4 Major End-Use

5 Market by Type

6 Price Overview

6.1 Price by Manufacturers

6.2 Price by End-Use

6.3 Price by Type

7 Research Conclusions

8 Appendix

8.1 Methodology

8.2 Research Data Source

Customization of the Report: This report can be modified to meet the clients requirements. Please connect with our sales squad (inquiry@globalmarketers.biz), who will guarantee that you get a report that suits your necessities.

To know More Details About Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market research Report @: https://www.globalmarketers.biz/report/pharma-&-healthcare/global-stem-cell-and-platelet-rich-plasma-(prp)-alopecia-therapies-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/141736 #table_of_contents

See the original post:
Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market By Trends, Analysis and Forecast to 2025. - Expedition 99

In 2018, the market size of HbA1c Analyzers Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for HbA1c Analyzers .

This report studies the global market size of HbA1c Analyzers , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @https://www.mrrse.com/sample/19996?source=atm

This study presents the HbA1c Analyzers Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. HbA1c Analyzers history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global HbA1c Analyzers market, the following companies are covered:

competitive landscape. The research report profiles key players of the HbA1c analyzers market, along with their strategies, products, and financials.

HbA1c Analyzers Market Segmentation

In order to present the impact of the crucial aspects, our analysts have formed key segments of the HbA1c analyzers market. The market has been segmented based on the product type, technology, modality, end user, and region. The report studies these segments in detail and offers reliable statistics and data regarding the growth of the HbA1c analyzers market.

Product Type

Technology

Modality

End User

Region

Equipment

Ion Exchange Chromatography

Portable HbA1c Analyzers

Hospitals

North America

Reagents & Consumables

Boronate Affinity HPLC

Benchtop HbA1c Analyzers

Diagnostic Centers

Latin America

HPLC

Academic and Research Institutes

Europe

Boronate Affinity Technology

South Asia

East Asia

Oceania

MEA

HbA1c Analyzers Market Key Questions Answered

The study on HbA1c analyzers market highlights distinguished and rare insight, in order to help the stakeholders gain exclusive information. Our analysts have answered numerous questions encircling the HbA1c analyzers market. Some of the questions answered in the report include:

HbA1c Analyzers Market Research Methodology

A systematic approach has been followed to draw crucial insights into the HbA1c analyzers market. Analysts at PMR follow a top-bottom and bottom-top approach to assess the HbA1c analyzers market and validate the information obtained from the primary as well as the secondary research methodology. In order to conduct primary research, interviews with a number of technology developers, distributors, manufacturers, key opinion leaders, and market heads were conducted.

Through the primary research, information about the key drivers and restraints, opportunities, winning strategies, regional value split, anticipated growth projections, and market concentrations has been acquired. In order to carry out secondary research, analysts at PMR studied numerous sources using essential sources. Some of the secondary sources include company websites, company annual reports, White papers, and financial reports. The paid publications that were referred to include BVD, Morningstar, Meltwaters, Genios, GBI, and Factiva. Through secondary research, information about the market share by region, industry growth projections, key insights on market segments, trends, and opportunities, can be obtained.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/19996?source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe HbA1c Analyzers product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of HbA1c Analyzers , with price, sales, revenue and global market share of HbA1c Analyzers in 2017 and 2018.

Chapter 3, the HbA1c Analyzers competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the HbA1c Analyzers breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

Buy This Report @ https://www.mrrse.com/checkout/19996?source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, HbA1c Analyzers market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe HbA1c Analyzers sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Originally posted here:
Personalized Medicine Market to Surge at a Robust Pace in Terms of Revenue Over 2016 2026 - Fusion Science Academy

The Global Cord Blood Stem Cell Market Research Report presents comprehensive information linked to the market. The updated market report assists clients to analyze better and predicts the Cord Blood Stem Cell market growth pattern at the global as well as regional level. Cord Blood Stem Cell Market 2020-2029 covers market characteristics, size, and growth, segmentation, regional divisions, Cord Blood Stem Cell competitive landscape, market shares, trends and plans for this market. Cord Blood Stem Cell market report provides an analysis of Cord Blood Stem Cell industry on the basis of popular market trends, types, top Organizations and variety of applications.

For better understanding, the Cord Blood Stem Cell Market study is organized in a chapter-wise manner.[Click To Get Detailed Table Of Contents]The report helps to See who are top Cord Blood Stem Cell key players, what benefits they Expect? Define the Key strength and success factor of Cord Blood Stem Cell. The worldwide Cord Blood Stem Cell industry also delivers the current market scenario based on report status, market maturity as well as the Cord Blood Stem Cell past and upcoming market trends which will boost the development of the Cord Blood Stem Cell industry. Additionally, the global market study provides essential industry frameworks along with key development methods and policies. The company divested its Cord Blood Stem Cell last year, which also impacted the Y-O-Y growth situations from 2020 to 2029.

For Better Understanding, Download Free Sample PDF Cord Blood Stem Cell Market Research Report @https://marketresearch.biz/report/cord-blood-stem-cells-market/request-sample

The detailed research report on Cord Blood Stem Cell Market gives an overview of the best players contributing to the industrial market and gives a wholly comprehensive look over the new records in the market. The primary vital manufacturers included in this report are Cord Blood Registry Systems Inc, Viacord Inc., China Cord Blood Corporation., Cord Blood America Inc, Cryo-Cell International Inc, Cryo-Save AG., Cordlife Group Ltd., Vita 34 AG., Lifecell International Pvt. Ltd., Stemcyte Inc.. This report begins with a market perspective and gives markets significant investment and the description of the worldwide Cord Blood Stem Cell market. The summary part of the report consists of Cord Blood Stem Cell market dynamics which covers market growth drivers, controlling elements, occasions and Cord Blood Stem Cell current trends together with the preference chain analysis and pricing detail study.

The report examines competition, product portfolios, and recent developments on the future Cord Blood Stem Cell Market.

Segmentation Covering:

Cord blood stem cell market segmentation by storage service:

Public cord blood bankPrivate cord blood bankCord blood stem cell market segmentation by application:

Blood diseaseCancerAcute leukaemiaKrabbe diseasesOther diseases

Regions Covering:

North America: US, Canada

Latin America: Brazil, Mexico, Rest of Latin America

Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe

Asia Pacific: China, India, Japan, Australia, South Korea, Rest of Asia Pacific

The Middle East and Africa: GCC, South Africa, Rest of Middle East and Africa

Inquire/Speak To Expert for Further Detailed Information About Cord Blood Stem Cell Report:https://marketresearch.biz/report/cord-blood-stem-cells-market/#inquiry

The research objectives of the Cord Blood Stem Cell Market are :

Analysis of Cord Blood Stem Cell market(Historical Data, Current, and Forecast) to analyze ratio of growth and Cord Blood Stem Cell market size.

Cord Blood Stem Cell Market risk, market opportunities, growth-driving forces, and confining factors of the business.

It provides a transparent research plan regarding the Cord Blood Stem Cell existing competitors together with rising ones.

New technologies and issues to investigate Cord Blood Stem Cell market dynamics.

Cord Blood Stem Cell Market Forecast 2020 to 2029.

Closely evaluate Cord Blood Stem Cell latest and developing market segments.

Cord Blood Stem Cell Market investigation with relevancy Cord Blood Stem Cell business value and volume.

Totally various strategies and approaches employed by competitors to reinforce growth in Cord Blood Stem Cell Market.

Finally, the research study provides a comprehensive view of the global Cord Blood Stem Cell market, offering market size and estimates for the period from 2020 to 2029.

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/cord-blood-stem-cells-market/#request-for-customization

Contact Us

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

See original here:
Global Cord Blood Stem Cell Market Size 2020 | Key Players, Growth Insights, Demand Analysis and 2029 Forecast Research - News Monitoring

Coherent Market Insightscame with a new study titledGlobal Cell Banking Outsourcing Market Analysis 2012-2017 and Forecast 2020-2027which is an in-depth study and analysis of the market, shading light on many noteworthy points and trends. Our industry experts, with unique domain knowledge, have developed this report to offer analysis of Market Size, Share, Future Growth, and Opportunity. An inclusive and decision-making data in this report will be useful for your esteemed clients.Cell Banking Outsourcing MarketGrowth Analysis by Top Key Manufacturers that definitely Up your businessCharles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd, Covance, Inc.

Download PDF with Recent all Updates & Trending Key Players with TOC: https://www.coherentmarketinsights.com/insight/request-pdf/1302

The study report validates the evaluation and volume of theCell Banking Outsourcing for the forthcoming years.Further it covers regions and country wise data that show a regional development status including market size, volume, value, and price. Then, the manufacturers data such as revenue, shipment, price, gross profit, interview record, and business distribution are also added. The aforementioned market is anticipated to reflect a positive growth trend between the years 2020 to 2027.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Cell Banking Outsourcing Market Taxonomy:

On the basis of type of bank:

On the basis of type of cell:

On the basis of phases of banking:

Ask more details or request custom reports to our experts at

The report then analyzes advancement and estimates development of the key players using the SWOT analysis. It also covers product categories, segments, competitive structure, new marketing plans, and collaborations. A detailed investigation on segments by market players, types, application, and geographical areas is also given in the report.

For competitor segment, the report includes global key players of Cell Banking Outsourcing as well as some small players. The details for each competitor include:

Main Business Information

SWOT Analysis

Sales, Revenue, Price and Gross Margin

Market Share

The market is controlled by these Renowned Players:

This report offers examination of the market in these districts covering, North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc.), Asia-Pacific (China, India, Japan, Southeast Asia etc.), South America (Brazil, Argentina etc.), Middle East & Africa (Saudi Arabia, South Africa etc.)with their crucial positions, size, production, consumption, revenue, and market share.

Download Exclusive Sample of this Premium Report at: https://www.coherentmarketinsights.com/insight/request-sample/1302

Market Segmented on the basis of Applications, size, product tye, technology amoung others.

Key Offerings of This Report:

Competitor Analysis Include:

Regional Market Analysis Market Analysis Market Overview 2012-2017 Local Supply, Import, Export, Local Consumption Analysis 2012-2017 Sales Price Analysis 2016 Market Share Analysis 2018-2023 Market Forecast, Growth, Opportunity

The report offers research conclusions, findingswhich can offer a summarized view of the Cell Banking Outsourcing. It then serves SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, demand, limit, supply, and market development rate and figure. The overall data was gathered by using many effective inquisitive tools like market attractiveness study, feasibility analyses, and predictable investment returns estimations.In short, the report encompasses all key entities regarding overall consequential study of the market.

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1302

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

Continue reading here:
Cell Banking Outsourcing Market Global Forecast to 2027 Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious...

In this section:

Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesnt make enoughor anyinsulin or doesnt use insulin well. Glucose then stays in your blood and doesnt reach your cells.

Over time, having too much glucose in your blood can cause health problems. Although diabetes has no cure, you can take steps to manage your diabetes and stay healthy.

Sometimes people call diabetes a touch of sugar or borderline diabetes. These terms suggest that someone doesnt really have diabetes or has a less serious case, but every case of diabetes is serious.

The most common types of diabetes are type 1, type 2, and gestational diabetes.

If you have type 1 diabetes, your body does not make insulin. Your immune system attacks and destroys the cells in your pancreas that make insulin. Type 1 diabetes is usually diagnosed in children and young adults, although it can appear at any age. People with type 1 diabetes need to take insulin every day to stay alive.

If you have type 2 diabetes, your body does not make or use insulin well. You can develop type 2 diabetes at any age, even during childhood. However, this type of diabetes occurs most often in middle-aged and older people. Type 2 is the most common type of diabetes.

Gestational diabetes develops in some women when they are pregnant. Most of the time, this type of diabetes goes away after the baby is born. However, if youve had gestational diabetes, you have a greater chance of developing type 2 diabetes later in life. Sometimes diabetes diagnosed during pregnancy is actually type 2 diabetes.

Less common types include monogenic diabetes, which is an inherited form of diabetes, and cystic fibrosis-related diabetes.

As of 2015, 30.3 million people in the United States, or 9.4 percent of the population, had diabetes. More than 1 in 4 of them didnt know they had the disease. Diabetes affects 1 in 4 people over the age of 65. About 90-95 percent of cases in adults are type 2 diabetes.1

You are more likely to develop type 2 diabetes if you are age 45 or older, have a family history of diabetes, or are overweight. Physical inactivity, race, and certain health problems such as high blood pressure also affect your chance of developing type 2 diabetes. You are also more likely to develop type 2 diabetes if you have prediabetes or had gestational diabetes when you were pregnant. Learn more about risk factors for type 2 diabetes.

Over time, high blood glucose leads to problems such as

You can take steps to lower your chances of developing these diabetes-related health problems.

[1] Centers for Disease Control and Prevention. National diabetes statistics report, 2017. Centers for Disease Control and Prevention website. http://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf (PDF, 1.3 MB) . Updated July, 18 2017. Accessed August 1, 2017.

See original here:
What is Diabetes? | NIDDK

NEW YORK, Jan. 21, 2020 /PRNewswire/ --

The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05774503/?utm_source=PRN

The market is driven by the factors such as, rising incidence of diabetes, growing geriatric population, increasing prevalence of obesity across the globe, and rapid technological advancement in diabetes care devices. However, the factors restraining the market growth are high cost of diabetes care devices and risks associated with the insulin delivery devices.Obesity, sedentary lifestyle and improper diet play a major role in increasing diabetes among the population worldwide.Physical activity is important to maintain the blood glucose level.

Lack of exercise and unhealthy diet such as diet high in fat and calories increase the risk for the development of obesity and diabetes.Obesity is one of the major problem and the biggest concern in all the communities across the globe.

Currently, more than one in two adults and nearly one in six children are obese.Obesity is one of the major issue affect people of all ages and incomes globally.

According to World Health Organization (WHO), in 2016, more than 1.9 billion adults aged 18 years and older were overweight. And out of these over 650 million adults were obese. Therefore, owing to these factors the market is likely to witness growth during the forecast period.Global diabetes care devices market was segmented by product and end user.The product segment was further divided as glucose monitoring devices and insulin delivery devices.

The glucose monitoring devices is further segmented into Glucometers, Lancets, Testing Strips and Other Glucose Monitoring Devices.The insulin delivery devices is further segmented into insulin pens, insulin syringes, insulin pumps and other insulin delivery devices.

The glucose monitoring devices is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes.Based on the end user the diabetes care device market is segmented into hospitals and clinics and home care.

The homecare held the major market share among the end user segment owing to ease of use, availability, and accessibility of insulin delivery devices.Some of the major primary and secondary sources included in the report for the diabetes care devices market are World Health Organization, American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes UK, Centers for Disease Control and Prevention, Chinese Diabetes Society, International Diabetes Federation and others.

Read the full report: https://www.reportlinker.com/p05774503/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-diabetes-care-devices-market-is-expected-to-reach-us-39-382-3-mn-in-2027-from-us-23-354-3-mn-in-2018--300990133.html

SOURCE Reportlinker

Follow this link:
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018 - Yahoo Finance

Danish company Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimers market, which isnt as unusual or unexpected as it initially sounds.

It has been postulated for some time that Alzheimers disease is related to blood glucose levels and has been dubbed type 3 diabetes. Type 1 is an autoimmune disease, sometimes referred to as insulin-dependent diabetes. Type 2 is typically acquired and appears more related to insulin resistance and is related to obesity.

Back in 2017, Mayo Clinic participated in a multi-institution clinical trial evaluating an insulin nasal spray on Alzheimers patients.

This study has furthered our understanding of the gene that is the strongest genetic risk factor known for Alzheimers disease, said Guojun Bu, a Mayo neuroscientist, at the time. About 20% of the human population carriers this riskier form of [the gene] APOE, called E4.

About 50% of Alzheimers cases are associated to APOE4 according to the study, which was published in the journal Neuron. And people with type 2 diabetes have a higher risk of Alzheimers disease, although the reasons for it are not completely clear. In fact, type 2 diabetes almost doubles the risk of developing Alzheimers disease. One possible reason is reduced blood flow to the brain because of damage to blood vessels caused by diabetes.

Now, Novo Nordisk is involved in a clinical trial using the companys GLP-1 analogue diabetes drug Victoza to evaluate if the drug can improve brain function and cognition in Alzheimers patients. It is a Phase IIb clinical trial. In laboratory studies it has been shown to improve Alzheimers symptoms and decrease the amount of amyloid plaques in the brain, which are associated with the disease.

In an update on the trial site, it was noted that patients receiving the drug had a perceived change in their symptoms after they stopped taking it. As a result, at the end of the 12-month trial, all patients will be offered the opportunity to join a 12-month open-label extension trial.

Novo Nordisk shares recently popped, and Evaluate Pharma speculates that this was related to the companys participation in the trial after the Danish newspaper Brsen made the link. They also cited a recent note by analysts at Bernstein titled Is Alzheimers type 3 diabetes? suggesting a role for GLP-1 drugs.

Despite the evidence, not a lot of clinical trials have been conducted testing the hypothesis. Evaluate Pharma notes, Correlation does not equal causation, and a skeptical pharma sector has remained on the sidelines. Indeed, it is striking that the number of clinical trials testing the hypothesis can be counted on the fingers of one hand, and none has a corporate pharma company sponsor.

These include studies by the University of Aarhus, which published data in 2016, the third Military Medical University, whose trial was completed last year but has not published the data yet, the trial mentioned earlier with the Imperial College London and Victoza, one by the Universitaria di Parma, with results expected last year, and an ongoing trial by the National Institute on Aging due in December 2022.

The trial of Victoza by the Imperial College London will enroll 204 patients with mild Alzheimers dementia and is a double-blind, placebo-controlled design that will last 12 months. Its primary endpoint is measuring rates of glucose metabolism in the brain. Secondary endpoints will look at various measures of cognition, including Adas, CDR-sum of boxes and ADSC-ADL.

The University of Aarhus study demonstrated that six months of Victoza was linked to an increase in glucose metabolism compared to placebo but was not deemed statistically significant.

Continued here:
Is Alzheimer's Type 3 Diabetes? Novo Nordisk is Willing to Find Out - BioSpace